Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Biogen agreed to acquire Apellis for $41.00 per share in cash (~$5.6bn upfront) plus nontransferable CVRs tied to SYFOVRE® sales, with close expected in Q2 2026. The deal adds two commercial products that generated $689m combined net sales in 2025 and are forecast to grow at a mid-to-high-teens CAGR at least through 2028; CVR structure could add up to $4/ share depending on SYFOVRE® sales milestones. Biogen expects the transaction to be accretive to non-GAAP diluted EPS starting in 2027, materially boost non-GAAP EPS CAGR through 2030, and accelerate its nephrology strategy around Phase 3 asset felzartamab (first readout H1 2027).

Analysis

This deal materially repositions Biogen from a neurology-first company toward a multi-domain specialty player; the practical lever is field-level capability transfer (sales reps, KOL relationships, REMS logistics) rather than R&D alone. Expect most commercial upside to be U.S.-centric and concentrated in specialty channels where uptake is driven by physician education, payer prior-authorizations and site infrastructure — meaning meaningful revenue and margin improvement will be realized on a multi-quarter to multi-year cadence as field teams are re-aligned and formularies negotiated.

Second-order competitive effects: smaller complement-targeting developers lose a standalone exit pathway (buyouts or co-promotions) while large pharmas will accelerate defensive moves — expect at least one rival to accelerate late-stage nephrology or retinal programs or to seek distribution tie-ups to protect market share. Supply-chain pressure will surface in specialty manufacturing and clinic capacity (injection clinics, infusion centers) where incremental demand can drive provider bargaining power and unit-cost tailwinds or headwinds depending on reimbursement progress.

Key risks and catalysts: integration and retention of commercial talent, payer coverage decisions, and safety-driven label/monitoring changes are the highest-probability negative outcomes that can compress adoption curves; conversely, strong readouts from the partner’s late-stage nephrology program or a simplified delivery device approval would be high-impact positive catalysts. Near-term monitoring priorities are: tender/close execution, commercial KPI cadence (prescriptions, new-to-brand rates, payer placements) over the next 6–12 months, and any emerging safety/regulatory signals that would materially change uptake assumptions.

Key Decisions for Investors

• Long BIIB equity (size 2–3% NAV) on any >5% intraday pullback; horizon 12–24 months. Rationale: diversification into nephrology/retina and expected EPS accretion medium term. Hedge: buy 12-month 15% OTM put as insurance (cost ~1–2% of position) to cap downside from integration or safety shocks.
• Event-arb small position in APLS (size 0.5–1% NAV) if tender spread to implied deal consideration exceeds 3%; horizon: until tender close (weeks–months). Risk: deal fail/competing bidder; reward: capture spread. Reduce position if regulatory objections surface or premium compresses <1%.
• Buy BIIB call spread to leverage upside with defined cost: buy 12–18 month slightly OTM call and sell 24–30% OTM call (size 0.75–1% NAV). Use this to express upside from successful integration and favorable readouts while limiting premium paid versus naked calls.
• Market-neutral hedge for rollout risk: pair 60% long BIIB equity / 40% long put protection (same-exposure notional) to keep convex upside but limit tail loss from safety/coverage setbacks. Re-evaluate once next major nephrology readout publishes (~12–18 months).